Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06696183 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

Study acronym: SEQUENCE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2025 to Apr 25, 2025
    v3
  2. Start date: Jan 2025 to Apr 2025
    • Primary completion date: Jan 2029 to Apr 2029
    • Study completion date: Jan 2030 to Apr 2030
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Explore the best tolerable and efficacious dose of Gilteritinib when combined with standard treatment with Venetoclax and Azacitidine in AML patients with FLT3 mutations which are ineligible for intensive chemotherapy
Trial Details
NCT Number NCT06696183
Lead Sponsor Technische Universität Dresden
Conditions
(from sponsor)		 AML - Acute Myeloid Leukemia
Related terms Leukemia, Myeloid, Acute
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov